University of California San Francisco

Qizhi Tang - 144
Qizhi
Tang
PhD

Professor of Surgery 
Division of Transplant Surgery 
Director, Transplantation Research Laboratory

Address

513 Parnassus Avenue, HSW, #1112
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-476-1739
Fax: 415-502-8326

ORCID: 0000-0001-7313-3574

Biography

The Tang lab focuses on translating knowledge on mechanisms of immune tolerance into novel therapeutics for treating autoimmune diabetes and preventing transplant rejection. Currently, two major areas of work are on therapeutic application of regulatory T cell therapy in type 1 diabetes and transplantation and immune modulation to enable immune suppression-free transplant of stem-cell-derived beta cells for treatment of type 1 diabetes.

Regulatory T cells are a small population of white blood cells that are essential for preventing tissue damages caused by over activation of the immune system. The Tang lab has shown that infusion of regulatory T cells in animal models can reverse type 1 diabetes, a disease caused by immune destruction of insulin-producing cells in the pancreatic islets. Similarly, regulatory T cell therapy can prevent rejection of transplanted organs in animal models. A joint team of researchers from the Tang and Bluestone labs is currently conducting 6 clinical trials evaluating the safety and efficacy of regulatory T cell therapy in patients. In the mean time, we are developing next generation regulatory T cell therapies in preclinical models to improve the safety and efficacy of the therapy.

In patients with chronic type 1 diabetes, transplanting of stem-cell-derived beta cells can potentially cure the disease, but patients have to commit to life-long immunosuppression to prevent rejection of the transplanted cells from rejection by the immune system. The Tang lab is currently investigating approaches to shield the transplanted cells from the immune systems using novel biomaterials developed in the Desai and Roy labs at UCSF. We are also applying genome-editing technologies to immunoengineer stem cells to evade immune rejection.

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2021
University of California Postdoctoral Studies Immunology 2002
Univeristy of Chicago Postdoctoral Studies Immunology 2000
University of Illinios PhD Microbiology and Immunology 1996
University of South Alabama Graduate School Microbiology and Immunology 1991
Peking Union Medical College Medical School Medcine 1989

Grants and Funding

  • Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM | CIRM | 2019-07-01 - 2023-06-30 | Role: Co-investigator
  • Islet transplant operational tolerance through minimization of ischemic injury and local immune regulation | JDRF | 2019-09-01 - 2021-08-31 | Role: PI
  • Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts | NIAID | 2014-07-01 - 2021-06-30 | Role: Co-investigator
  • Multiplex in situ gene expression and phenotypical profiling of inflamed tissues | NIH | 2015-06-26 - 2021-05-31 | Role: Co-Principal Investigator
  • Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation | NIH | 2014-06-01 - 2021-05-31 | Role: Co-Principal Investigator
  • Diabetes Research Center | NIH | 2002-09-01 - 2021-03-31 | Role: Co-Investigator
  • Engineering Treg cells to treat type 1 diabetes | Helmsley Charitable Trust | 2017-11-01 - 2020-10-31 | Role: PI
  • Promoting extrahepatic engraftment of human islets by parathyroid gland co-transplantation | JDRF | 2018-06-01 - 2019-05-31 | Role: PI
  • Regulatory 'T' Cell Control of Autoimmune Diabetes. | NIH | 2010-03-15 - 2016-02-29 | Role: Principal Investigator
  • Donor-Specific Regulatory T Cell Therapy in Liver Transplantation | NIH | 2012-04-01 - 2014-03-31 | Role: Co-Principal Investigator
  • BD FACS ARIA II CELL SORTER | NIH | 2010-02-01 - 2011-01-31 | Role: Principal Investigator
  • Visualizing regulatory T cell control of autoimmunity | NIH | 2005-07-01 - 2008-06-30 | Role: Principal Investigator
  • T CELL ACTIVATION AND ANERGY INDUCTION BY ANTI-CD3 | NIH | 2000-02-01 - 1900-01-01 | Role: Principal Investigator

Research Interests

T-Lymphocyte Subsets

T-Lymphocytes

Suppressor-Effector

Autoimmunity

Islets of Langerhans Transplantation

Transplantation Immunology

Transplantation Tolerance

Immune Tolerance

Immunotherapy

Research Pathways

Basic Biomedical & Translational Research

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 122
  1. Harnessing regulatory T cells to establish immune tolerance.
    Ho P, Cahir-McFarland E, Fontenot JD, Lodie T, Nada A, Tang Q, Turka LA, Bluestone JA| | PubMed
  2. Precise surface functionalization of PLGA particles for human T cell modulation.
    Hadley P, Chen Y, Cline L, Han Z, Tang Q, Huang X, Desai T| | PubMed
  3. Epidermal Stem Cell Derived Exosomes Alleviate Excessive Autophagy Induced Endothelial Cell Apoptosis by Delivering miR200b-3p to Diabetic Wounds.
    Xu H, Yang H, Wang Z, Tang Q, Cao X, Chen C, Dong Y, Xu Z, Lv D, Rong Y, Chen M, Tang B, Deng W, Zhu J, Hu Z| | PubMed
  4. Feasibility of an implantable bioreactor for renal cell therapy using silicon nanopore membranes.
    Kim EJ, Chen C, Gologorsky R, Santandreu A, Torres A, Wright N, Goodin MS, Moyer J, Chui BW, Blaha C, Brakeman P, Vartanian S, Tang Q, David Humes H, Fissell WH, Roy S| | PubMed
  5. Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes.
    Obarorakpor N, Patel D, Boyarov R, Amarsaikhan N, Cepeda JR, Eastes D, Robertson S, Johnson T, Yang K, Tang Q, Zhang L| | PubMed
  6. Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial.
    Guinan EC, Contreras-Ruiz L, Crisalli K, Rickert C, Rosales I, Makar R, Colvin R, Geissler EK, Sawitzki B, Harden P, Tang Q, Blancho G, Turka LA, Markmann JF| | PubMed
  7. Regulatory T cells aid stem-cell therapy for Parkinson's disease.
    Tang Q| | PubMed
  8. Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space.
    Chendke GS, Kharbikar BN, Ashe S, Faleo G, Sneddon JB, Tang Q, Hebrok M, Desai TA| | PubMed
  9. Impact of interleukin-6 on T cells in kidney transplant recipients.
    Chandran S, Tang Q| | PubMed
  10. The dichotomous outcomes of TNFα signaling in CD4+ T cells.
    Skartsis N, Ferreira LMR, Tang Q| | PubMed
  11. Selective decrease of donor-reactive Tregs after liver transplantation limits Treg therapy for promoting allograft tolerance in humans.
    Tang Q, Leung J, Peng Y, Sanchez-Fueyo A, Lozano JJ, Lam A, Lee K, Greenland JR, Hellerstein M, Fitch M, Li KW, Esensten JH, Putnam AL, Lares A, Nguyen V, Liu W, Bridges ND, Odim J, Demetris AJ, Levitsky J, Taner T, Feng S| | PubMed
  12. A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients.
    Moreau A, Kervella D, Bouchet-Delbos L, Braudeau C, Saïagh S, Guérif P, Limou S, Moreau A, Bercegeay S, Streitz M, Sawitzki B, James B, Harden PN, Game D, Tang Q, Markmann JF, Roberts ISD, Geissler EK, Dréno B, Josien R, Cuturi MC, Blancho G, DIVAT consortium| | PubMed
  13. Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival.
    Wagner JC, Ronin E, Ho P, Peng Y, Tang Q| | PubMed
  14. IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function.
    Skartsis N, Peng Y, Ferreira LMR, Nguyen V, Ronin E, Muller YD, Vincenti F, Tang Q| | PubMed
  15. Lung transplant recipients with idiopathic pulmonary fibrosis have impaired alloreactive immune responses.
    Wang P, Leung J, Lam A, Lee S, Calabrese DR, Hays SR, Golden JA, Kukreja J, Singer JP, Wolters PJ, Tang Q, Greenland JR| | PubMed
  16. Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience.
    Balcerek J, Shy BR, Putnam AL, Masiello LM, Lares A, Dekovic F, Acevedo L, Lee MR, Nguyen V, Liu W, Paruthiyil S, Xu J, Leinbach AS, Bluestone JA, Tang Q, Esensten JH| | PubMed
  17. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
    Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA| | PubMed
  18. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
    Muller YD, Ferreira LMR, Ronin E, Ho P, Nguyen V, Faleo G, Zhou Y, Lee K, Leung KK, Skartsis N, Kaul AM, Mulder A, Claas FHJ, Wells JA, Bluestone JA, Tang Q| | PubMed
  19. The Role of Regulatory T Cells in Pulmonary Arterial Hypertension.
    Tian W, Jiang SY, Jiang X, Tamosiuniene R, Kim D, Guan T, Arsalane S, Pasupneti S, Voelkel NF, Tang Q, Nicolls MR| | PubMed
  20. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection.
    Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, Tang Q, Hebrok M| | PubMed
  21. A Comparison of Ex Vivo Expanded Human Regulatory T Cells Using Allogeneic Stimulated B Cells or Monocyte-Derived Dendritic Cells.
    Lee LM, Zhang H, Lee K, Liang H, Merleev A, Vincenti F, Maverakis E, Thomson AW, Tang Q| | PubMed
  22. A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance.
    Warshauer JT, Belk JA, Chan AY, Wang J, Gupta AR, Shi Q, Skartsis N, Peng Y, Phipps JD, Acenas D, Smith JA, Tamaki SJ, Tang Q, Gardner JM, Satpathy AT, Anderson MS| | PubMed
  23. The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.
    Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, Congrave-Wilson Z, Roth TL, Eyquem J, Van Gool F, Marson A, Perez L, Wells JA, Bluestone JA, Tang Q| | PubMed
  24. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial.
    Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG| | PubMed
  25. Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes.
    Bluestone JA, Tang Q| | PubMed
  26. Functional CRISPR dissection of gene networks controlling human regulatory T cell identity.
    Schumann K, Raju SS, Lauber M, Kolb S, Shifrut E, Cortez JT, Skartsis N, Nguyen VQ, Woo JM, Roth TL, Yu R, Nguyen MLT, Simeonov DR, Nguyen DN, Targ S, Gate RE, Tang Q, Bluestone JA, Spitzer MH, Ye CJ, Marson A| | PubMed
  27. CAR-Tregs as a Strategy for Inducing Graft Tolerance.
    Wagner JC, Tang Q| | PubMed
  28. Novel In Situ Hybridization and Multiplex Immunofluorescence Technology Combined With Whole-slide Digital Image Analysis in Kidney Transplantation.
    Junger H, Dobi D, Chen A, Lee L, Vasquez JJ, Tang Q, Laszik ZG| | PubMed
  29. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
    Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, Tang Q, Guinan EC, Battaglia M, Burlingham WJ, Roberts ISD, Streitz M, Josien R, Böger CA, Scottà C, Markmann JF, Hester JL, Juerchott K, Braudeau C, James B, Contreras-Ruiz L, van der Net JB, Bergler T, Caldara R, Petchey W, Edinger M, Dupas N, Kapinsky M, Mutzbauer I, Otto NM, Öllinger R, Hernandez-Fuentes MP, Issa F, Ahrens N, Meyenberg C, Karitzky S, Kunzendorf U, Knechtle SJ, Grinyó J, Morris PJ, Brent L, Bushell A, Turka LA, Bluestone JA, Lechler RI, Schlitt HJ, Cuturi MC, Schlickeiser S, Friend PJ, Miloud T, Scheffold A, Secchi A, Crisalli K, Kang SM, Hilton R, Banas B, Blancho G, Volk HD, Lombardi G, Wood KJ, Geissler EK| | PubMed
  30. Next-generation regulatory T cell therapy.
    Ferreira LMR, Muller YD, Bluestone JA, Tang Q| | PubMed
  31. Supporting Survival of Transplanted Stem-Cell-Derived Insulin-Producing Cells in an Encapsulation Device Augmented with Controlled Release of Amino Acids.
    Chendke GS, Faleo G, Juang C, Parent AV, Bernards DA, Hebrok M, Tang Q, Desai TA| | PubMed
  32. NextGen cell-based immunotherapies in cancer and other immune disorders.
    Azimi CS, Tang Q, Roybal KT, Bluestone JA| | PubMed
  33. NKG2C Natural Killer Cells in Bronchoalveolar Lavage Are Associated With Cytomegalovirus Viremia and Poor Outcomes in Lung Allograft Recipients.
    Calabrese DR, Chong T, Wang A, Singer JP, Gottschall M, Hays SR, Golden JA, Kukreja J, Lanier LL, Tang Q, Greenland JR| | PubMed
  34. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.
    Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers of Excellence| | PubMed
  35. Early expansion of donor-specific Tregs in tolerant kidney transplant recipients.
    Savage TM, Shonts BA, Obradovic A, Dewolf S, Lau S, Zuber J, Simpson MT, Berglund E, Fu J, Yang S, Ho SH, Tang Q, Turka LA, Shen Y, Sykes M| | PubMed
  36. Islet encapsulation therapy - racing towards the finish line?
    Desai TA, Tang Q| | PubMed
  37. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier.
    Esensten JH, Muller YD, Bluestone JA, Tang Q| | PubMed
  38. Treg cells-the next frontier of cell therapy.
    Bluestone JA, Tang Q| | PubMed
  39. Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells.
    Odorico J, Markmann J, Melton D, Greenstein J, Hwa A, Nostro C, Rezania A, Oberholzer J, Pipeleers D, Yang L, Cowan C, Huangfu D, Egli D, Ben-David U, Vallier L, Grey ST, Tang Q, Roep B, Ricordi C, Naji A, Orlando G, Anderson DG, Poznansky M, Ludwig B, Tomei A, Greiner DL, Graham M, Carpenter M, Migliaccio G, D'Amour K, Hering B, Piemonti L, Berney T, Rickels M, Kay T, Adams A| | PubMed
  40. Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.
    Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M| | PubMed
  41. Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.
    Greenland JR, Chong T, Wang AS, Martinez E, Shrestha P, Kukreja J, Hays SR, Golden JA, Singer JP, Tang Q| | PubMed
  42. Revealing the specificity of regulatory T cells in murine autoimmune diabetes.
    Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q| | PubMed
  43. Alloreactive fetal T cells promote uterine contractility in preterm labor via IFN-γ and TNF-α.
    Frascoli M, Coniglio L, Witt R, Jeanty C, Fleck-Derderian S, Myers DE, Lee TH, Keating S, Busch MP, Norris PJ, Tang Q, Cruz G, Barcellos LF, Gomez-Lopez N, Romero R, MacKenzie TC| | PubMed
  44. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.
    Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grzes D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P| | PubMed
  45. Mitigating Ischemic Injury of Stem Cell-Derived Insulin-Producing Cells after Transplant.
    Faleo G, Russ HA, Wisel S, Parent AV, Nguyen V, Nair GG, Freise JE, Villanueva KE, Szot GL, Hebrok M, Tang Q| | PubMed
  46. Nanoporous Immunoprotective Device for Stem-Cell-Derived β-Cell Replacement Therapy.
    Chang R, Faleo G, Russ HA, Parent AV, Elledge SK, Bernards DA, Allen JL, Villanueva K, Hebrok M, Tang Q, Desai TA| | PubMed
  47. Transplant trials with Tregs: perils and promises.
    Tang Q, Vincenti F| | PubMed
  48. Cutting Edge: Origins, Recruitment, and Regulation of CD11c+ Cells in Inflamed Islets of Autoimmune Diabetes Mice.
    Klementowicz JE, Mahne AE, Spence A, Nguyen V, Satpathy AT, Murphy KM, Tang Q| | PubMed
  49. Glucose-Stimulated Insulin Response of Silicon Nanopore-Immunoprotected Islets under Convective Transport.
    Song S, Yeung R, Park J, Posselt AM, Desai TA, Tang Q, Roy S| | PubMed
  50. Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.
    Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, Jones KL, Gottlieb PA, Kappler JW, Tang Q, Roep BO, Atkinson MA, Mathews CE, Nakayama M| | PubMed
  51. Impact of Immune-Modulatory Drugs on Regulatory T Cell.
    Furukawa A, Wisel SA, Tang Q| | PubMed
  52. Restoring Regulatory T Cells in Type 1 Diabetes.
    Spence A, Tang Q| | PubMed
  53. Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts.
    Greenland JR, Wong CM, Ahuja R, Wang AS, Uchida C, Golden JA, Hays SR, Leard LE, Rajalingam R, Singer JP, Kukreja J, Wolters PJ, Caughey GH, Tang Q| | PubMed
  54. Virtual Global Transplant Laboratory Standard Operating Procedures for Blood Collection, PBMC Isolation, and Storage.
    Higdon LE, Lee K, Tang Q, Maltzman JS| | PubMed
  55. Assessment of Immune Isolation of Allogeneic Mouse Pancreatic Progenitor Cells by a Macroencapsulation Device.
    Faleo G, Lee K, Nguyen V, Tang Q| | PubMed
  56. Heightened Immune Activation in Fetuses with Gastroschisis May Be Blocked by Targeting IL-5.
    Frascoli M, Jeanty C, Fleck S, Moradi PW, Keating S, Mattis AN, Tang Q, MacKenzie TC| | PubMed
  57. Silicon nanopore membrane (SNM) for islet encapsulation and immunoisolation under convective transport.
    Song S, Faleo G, Yeung R, Kant R, Posselt AM, Desai TA, Tang Q, Roy S| | PubMed
  58. Approaching a cure for type 1 diabetes.
    Tang Q, Desai TA| | PubMed
  59. Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation.
    Zhang M, Tang Q| | PubMed
  60. Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
    Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q| | PubMed
  61. Targeting Treg signaling for the treatment of autoimmune diseases.
    Spence A, Klementowicz JE, Bluestone JA, Tang Q| | PubMed
  62. Therapeutic window of interleukin-2 for autoimmune diseases.
    Tang Q| | PubMed
  63. Polycaprolactone Thin-Film Micro- and Nanoporous Cell-Encapsulation Devices.
    Nyitray CE, Chang R, Faleo G, Lance KD, Bernards DA, Tang Q, Desai TA| | PubMed
  64. Immunotherapy: making the case for precision medicine.
    Bluestone JA, Tang Q| | PubMed
  65. Increased maternal T cell microchimerism in the allogeneic fetus during LPS-induced preterm labor in mice.
    Wegorzewska M, Le T, Tang Q, MacKenzie TC| | PubMed
  66. Therapeutic regulatory T cells subvert effector T cell function in inflamed islets to halt autoimmune diabetes.
    Mahne AE, Klementowicz JE, Chou A, Nguyen V, Tang Q| | PubMed
  67. Antigen recognition in the islets changes with progression of autoimmune islet infiltration.
    Lindsay RS, Corbin K, Mahne A, Levitt BE, Gebert MJ, Wigton EJ, Bradley BJ, Haskins K, Jacobelli J, Tang Q, Krummel MF, Friedman RS| | PubMed
  68. Interpretation of transplant biopsies and immune responses following Treg cell therapy.
    Tang Q, Kang SM| | PubMed
  69. Fetal intervention increases maternal T cell awareness of the foreign conceptus and can lead to immune-mediated fetal demise.
    Wegorzewska M, Nijagal A, Wong CM, Le T, Lescano N, Tang Q, MacKenzie TC| | PubMed
  70. Regulatory T-cell therapy in transplantation: moving to the clinic.
    Tang Q, Bluestone JA| | PubMed
  71. Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice.
    Nijagal A, Derderian C, Le T, Jarvis E, Nguyen L, Tang Q, Mackenzie TC| | PubMed
  72. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients.
    Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F| | PubMed
  73. IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress.
    Lerner AG, Upton JP, Praveen PV, Ghosh R, Nakagawa Y, Igbaria A, Shen S, Nguyen V, Backes BJ, Heiman M, Heintz N, Greengard P, Hui S, Tang Q, Trusina A, Oakes SA, Papa FR| | PubMed
  74. Regulatory T-cell therapy for transplantation: how many cells do we need?
    Tang Q, Lee K| | PubMed
  75. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.
    Tang Q, Bluestone JA, Kang SM| | PubMed
  76. B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice.
    Scapini P, Lamagna C, Hu Y, Lee K, Tang Q, DeFranco AL, Lowell CA| | PubMed
  77. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.
    Penaranda C, Tang Q, Bluestone JA| | PubMed
  78. Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts.
    Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM| | PubMed
  79. The maternal immune response inhibits the success of in utero hematopoietic cell transplantation.
    Nijagal A, Wegorzewska M, Le T, Tang Q, Mackenzie TC| | PubMed
  80. Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice.
    Nijagal A, Wegorzewska M, Jarvis E, Le T, Tang Q, MacKenzie TC| | PubMed
  81. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.
    Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E| | PubMed
  82. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.
    Penaranda C, Tang Q, Ruddle NH, Bluestone JA| | PubMed
  83. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
    Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA| | PubMed
  84. Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues.
    Melli K, Friedman RS, Martin AE, Finger EB, Miao G, Szot GL, Krummel MF, Tang Q| | PubMed
  85. T regulatory cells in autoimmune diabetes: past challenges, future prospects.
    Bluestone JA, Tang Q, Sedwick CE| | PubMed
  86. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice.
    Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA| | PubMed
  87. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.
    Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA| | PubMed
  88. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.
    Tang Q, Bluestone JA| | PubMed
  89. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice.
    Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D| | PubMed
  90. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
    Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC| | PubMed
  91. Mechanisms of PDL1-mediated regulation of autoimmune diabetes.
    Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH| | PubMed
  92. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.
    Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA| | PubMed
  93. Regulatory T-cell physiology and application to treat autoimmunity.
    Tang Q, Bluestone JA| | PubMed
  94. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells.
    Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI| | PubMed
  95. Imaging the function of regulatory T cells in vivo.
    Tang Q, Krummel MF| | PubMed
  96. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship?
    Tang Q, Bluestone JA| | PubMed
  97. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.
    Masteller EL, Tang Q, Bluestone JA| | PubMed
  98. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.
    Trenado A, Sudres M, Tang Q, Maury S, Charlotte F, Grégoire S, Bonyhadi M, Klatzmann D, Salomon BL, Cohen JL| | PubMed
  99. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice.
    Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA| | PubMed
  100. How do CD4+CD25+ regulatory T cells control autoimmunity?
    Bluestone JA, Tang Q| | PubMed
  101. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.
    Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA| | PubMed
  102. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function.
    Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA| | PubMed
  103. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.
    Bluestone JA, Tang Q| | PubMed
  104. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.
    Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA| | PubMed
  105. Notch 1 signaling regulates peripheral T cell activation.
    Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA| | PubMed
  106. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells.
    Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA| | PubMed
  107. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo.
    Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone JA| | PubMed
  108. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment.
    Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA| | PubMed
  109. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells.
    Boden E, Tang Q, Bour-Jordan H, Bluestone JA| | PubMed
  110. The Src family kinase Fyn mediates signals induced by TCR antagonists.
    Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA| | PubMed
  111. ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse.
    Allenspach EJ, Cullinan P, Tong J, Tang Q, Tesciuba AG, Cannon JL, Takahashi SM, Morgan R, Burkhardt JK, Sperling AI| | PubMed
  112. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide.
    O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA| | PubMed
  113. Development and applications of surface-linked single chain antibodies against T-cell antigens.
    Griffin MD, Holman PO, Tang Q, Ashourian N, Korthäuer U, Kranz DM, Bluestone JA| | PubMed
  114. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.
    Smith JA, Tang Q, Bluestone JA| | PubMed
  115. T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis.
    Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA| | PubMed
  116. Proinflammatory functions of IL-2 in herpes simplex virus corneal infection.
    Tang Q, Chen W, Hendricks RL| | PubMed
  117. Interferon gamma regulates platelet endothelial cell adhesion molecule 1 expression and neutrophil infiltration into herpes simplex virus-infected mouse corneas.
    Tang Q, Hendricks RL| | PubMed
  118. Ex vivo model of leukocyte migration into herpes simplex virus-infected mouse corneas.
    Chen W, Tang Q, Hendricks RL| | PubMed
  119. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection.
    Liu T, Tang Q, Hendricks RL| | PubMed
  120. Involvement of LFA-1 and ICAM-1 in the herpetic disease resulting from HSV-1 corneal infection.
    Dennis RF, Siemasko KF, Tang Q, Hendricks RL, Finnegan A| | PubMed
  121. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells.
    Dingwell KS, Brunetti CR, Hendricks RL, Tang Q, Tang M, Rainbow AJ, Johnson DC| | PubMed
  122. IL-8 gene expression in cultures of human corneal epithelial cells and keratocytes.
    Cubitt CL, Tang Q, Monteiro CA, Lausch RN, Oakes JE| | PubMed